Supplementary Figure 4 from ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer

Key Points

• Circulating tumor DNA analysis identifies double minutes, indicating genetic alterations in cancer cells.
• Whole-genome sequencing highlights the presence of HER2 alterations in ctDNA, suggesting a potential target for therapy.
• This investigation provides insights into the genetic landscape of metastatic urothelial cancer via tumor DNA analysis.
• The findings may enhance monitoring strategies for patients with metastatic urothelial cancer through ctDNA assessment.